Denali Therapeutics Inc. - COMMON STOCK (DNLI) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2017 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
DNLI on Nasdaq
Shares outstanding
147,179,178
Price per share
$16.51
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
135,496,666
Total reported value
$1,967,413,087
% of total 13F portfolios
0.01%
Share change
-2,221,408
Value change
-$29,612,977
Number of holders
235
Price from insider filings
$16.51
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Denali Therapeutics Inc. - COMMON STOCK (DNLI) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 7.2% $133,230,747 10,490,610 BlackRock, Inc. 31 Mar 2025
FMR LLC 5.8% $123,948,417 8,536,392 FMR LLC 30 Sep 2025
WELLINGTON MANAGEMENT GROUP LLP 3.9% $79,249,615 5,664,733 Wellington Management Group LLP 30 Jun 2025
Capital Research Global Investors 3.8% $69,560,580 5,477,211 Capital Research Global Investors 31 Dec 2024
BAILLIE GIFFORD & CO 5.6% -23% $36,149,768 -$8,897,509 2,198,891 -20% BAILLIE GIFFORD & CO 30 Jun 2025

As of 30 Sep 2025, 235 institutional investors reported holding 135,496,666 shares of Denali Therapeutics Inc. - COMMON STOCK (DNLI). This represents 92% of the company’s total 147,179,178 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Denali Therapeutics Inc. - COMMON STOCK (DNLI) together control 74% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 8.4% 12,289,626 +2% 0% $178,445,369
VANGUARD GROUP INC 8.1% 11,992,918 +1.5% 0% $174,137,169
BAILLIE GIFFORD & CO 7.9% 11,591,585 -3% 0.12% $168,309,813
FMR LLC 4.3% 6,340,316 -16% 0% $92,061,393
T. Rowe Price Investment Management, Inc. 3.8% 5,638,567 +74% 0.05% $81,872,000
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC 3.7% 5,465,037 -13% 0.02% $79,352,339
STATE STREET CORP 3.7% 5,464,261 +21% 0% $79,341,070
Temasek Holdings (Private) Ltd 3.6% 5,355,832 0% 0.27% $77,766,681
Capital Research Global Investors 3.2% 4,760,858 +0.22% 0.01% $69,127,658
PRICE T ROWE ASSOCIATES INC /MD/ 3.1% 4,568,368 -31% 0.01% $66,333,000
BAKER BROS. ADVISORS LP 2.5% 3,731,695 0% 0.39% $54,184,211
ALLIANCEBERNSTEIN L.P. 2.4% 3,520,414 +12% 0.02% $51,116,411
GEODE CAPITAL MANAGEMENT, LLC 2.4% 3,466,057 +9.3% 0% $50,335,167
Crestline Management, LP 2.3% 3,410,732 -12% 85% $49,523,829
Holocene Advisors, LP 2.1% 3,135,712 +678% 0.1% $45,530,538
Point72 Asset Management, L.P. 1.7% 2,519,535 +14% 0.08% $36,583,650
DIMENSIONAL FUND ADVISORS LP 1.6% 2,357,214 -2.3% 0.01% $34,226,491
GOLDMAN SACHS GROUP INC 1.5% 2,163,705 +16% 0% $31,416,997
UBS Group AG 1.4% 2,012,353 +112% 0.01% $29,219,365
STEMPOINT CAPITAL LP 1.2% 1,734,659 +145% 5.1% $25,187,249
MORGAN STANLEY 1.1% 1,689,492 +29% 0% $24,531,439
Fisher Asset Management, LLC 1.1% 1,631,496 +7.6% 0.01% $23,689,321
MILLENNIUM MANAGEMENT LLC 0.89% 1,307,171 +45% 0.01% $18,980,123
PRINCIPAL FINANCIAL GROUP INC 0.86% 1,271,190 +18% 0.01% $18,457,679
NORTHERN TRUST CORP 0.84% 1,234,179 +2.7% 0% $17,920,279

Institutional Holders of Denali Therapeutics Inc. - COMMON STOCK (DNLI) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 2,675,442 $44,171,785 +$17,587,936 $16.51 20
2025 Q3 135,496,666 $1,967,413,087 -$29,612,977 $14.52 235
2025 Q2 137,594,175 $1,925,023,022 +$63,128,644 $13.99 228
2025 Q1 132,874,634 $1,807,534,840 +$50,388,755 $13.60 219
2024 Q4 127,918,322 $2,606,945,002 +$19,549,827 $20.38 221
2024 Q3 126,357,167 $3,680,165,886 +$76,196,259 $29.13 215
2024 Q2 119,614,175 $2,777,409,220 +$110,937,376 $23.22 202
2024 Q1 121,129,498 $2,485,853,165 +$124,876,915 $20.52 208
2023 Q4 4,670,024 $96,733,812 -$3,645,391 $21.46 4
2023 Q3 107,839,117 $2,224,760,143 +$10,695,553 $20.63 191
2023 Q2 106,694,834 $3,148,558,535 -$754,311 $29.51 195
2023 Q1 107,882,145 $2,484,889,935 +$45,523,771 $23.04 195
2022 Q4 105,756,695 $2,941,077,381 +$354,688,172 $27.81 190
2022 Q3 91,624,821 $2,811,570,719 -$38,245,613 $30.69 187
2022 Q2 92,157,220 $2,712,102,127 +$189,300,850 $29.43 172
2022 Q1 86,541,948 $2,784,525,759 +$41,733,879 $32.17 172
2021 Q4 85,195,627 $3,799,942,368 +$12,226,688 $44.60 201
2021 Q3 84,789,652 $4,278,426,976 +$169,776,157 $50.45 206
2021 Q2 77,750,105 $6,097,458,707 +$33,999,316 $78.44 205
2021 Q1 77,712,457 $4,436,868,770 +$73,562,778 $57.10 211
2020 Q4 66,014,536 $5,528,696,915 +$204,274,299 $83.76 197
2020 Q3 82,543,810 $2,957,682,334 +$14,823,264 $35.83 165
2020 Q2 82,625,820 $1,997,882,520 +$63,459,910 $24.18 139
2020 Q1 80,140,725 $1,403,267,222 +$148,038,169 $17.51 123
2019 Q4 70,718,085 $1,231,893,094 -$9,090,266 $17.42 106
2019 Q3 71,153,301 $1,090,104,879 -$4,834,646 $15.32 110
2019 Q2 71,323,010 $1,480,644,493 +$62,486,957 $20.76 111
2019 Q1 68,854,243 $1,598,840,118 +$23,453,607 $23.22 111
2018 Q4 68,033,725 $1,405,546,161 -$869,690 $20.66 86
2018 Q3 66,971,326 $1,455,928,654 +$108,766,089 $21.74 76
2018 Q2 62,206,479 $948,642,603 +$18,838,767 $15.25 66
2018 Q1 60,832,830 $1,196,651,992 +$60,184,105 $19.69 56
2017 Q4 58,142,948 $909,284,000 +$768,126,565 $15.64 44